wo papers in The New England Journal of Medicine report success in new malaria vaccines, said Ed Silverman in Pharmalot. Given to children in Africa, the vaccines reduced malaria infections by up to 65 percent, compared with a test group. The trials were in Tanzania and Kenya, where “use of bed nets and anti-malarial drugs have dramatically reduced the number of malaria cases” already. Researchers can now move to more malaria-stricken areas.
This news “is good—fantastic, in fact,” said Elizabeth Dickenson in Foreign Policy online. First, we’ve never come up with a vaccine against a human parasite before, and malaria is a “capricious and classically difficult-to-fight parasitic infection.” Also, this is the first malaria vaccine given in conjunction with other vaccines, like polio and MMR, and “there was no interference on either side.”
Still, “no one pretends that even with these results malaria is anywhere near beaten,” said Jeffrey Kluger in Time. Before it can reach the nearly one million people who die of the disease each year, the drug needs two more years of testing and more time in “the bureaucratic labyrinth of the approval process.” Even so, the vaccine does bring us “closer to the moment when today’s plague becomes yesterday’s memory.”
THE WEEK'S AUDIOPHILE PODCASTS: LISTEN SMARTER
- 31 TV shows to watch in 2014
- Why would a young person today be religious?
- The world's dumbest idea: Taxing solar energy
- He said he was leaving. She ignored him.
- Israel and Russia are getting along. Have the neocons noticed?
- Why Good Friday is so important to Christians
- Why we can't stop procrastinating, according to science
- The 6-year-old who woke up from a coma with a different personality
- Why I'm a pro-life liberal
- Why Holy Thursday is so important to Christians
Subscribe to the Week